# Home-based self-administered transcranial direct current stimulation for women affected by primary dysmenorrhoea in Northeastern Brazil: a protocol study

**Authors:** Tatiana Camila de Lima Alves da Silva, Yvinna Tamiris Rodrigues, Edson Silva-Filho, Paloma Cristina Alves de Oliveira, Thiago Anderson Brito De Araújo, Ervinas Bernatavicius, Alexander Anthony Cook, Emilè Radytè, Rodrigo Pegado, Maria Thereza Micussi

PMC · DOI: 10.1136/bmjopen-2025-100964 · 2025-07-13

## TL;DR

This study tests if home-based brain stimulation can reduce menstrual pain and improve quality of life for women with primary dysmenorrhoea.

## Contribution

It introduces a novel protocol for self-administered tDCS at home to address central nervous system dysfunction in dysmenorrhoea.

## Key findings

- Home-based tDCS will be evaluated for its effects on pain and mental health in women with primary dysmenorrhoea.
- The study will assess outcomes like quality of life and electroencephalography changes over multiple menstrual cycles.

## Abstract

The prevalence of women with primary dysmenorrhoea is high and negatively impacts physical and mental health. The intense cyclic episodes of pain generate central nervous system dysfunctional processing. In this sense, strategies focused on the central nervous system are important to re-establish normal functioning. Home-based self-administered transcranial direct current stimulation (tDCS) emerges as a strategy to modulate dysfunctional brain areas and improve the symptoms. This protocol aims to evaluate the effects of home-based self-administered tDCS for pain, premenstrual symptoms, physical performance, quality of life, electroencephalography and patient global impression in women affected by primary dysmenorrhoea.

This is a single-centre, parallel, randomised, double-blinded clinical trial protocol. 40 women affected by primary dysmenorrhoea will be randomised into two groups (active-tDCS or sham-tDCS). Then, 20 consecutive sessions of home-based self-administered tDCS will be performed. The assessments will occur at five time points: baseline, after the 20th sessions, at the first, second and third cycles after tDCS interventions (follow-ups). Primary outcome will be pain according to visual analogue scale. Quality of life, premenstrual symptoms screening, depression, anxiety, physical performance, electroencephalography and participants’ satisfaction will be the secondary outcomes. A mixed analysis of variance will calculate the effect of stimulation.

The study was approved by the ethics committee of the Federal University of Rio Grande do Norte (No. 6.037.756) and registered in the Brazilian Clinical Trials Registry (n° RBR-747k8vb). Participants may withdraw at any time without penalty. Free support will be available from the lead researcher if needed. All procedures will follow Good Clinical Practice and international ethical standards.

https://ensaiosclinicos.gov.br/rg/RBR-747k8vb

## Full-text entities

- **Genes:** TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}
- **Diseases:** depression (MESH:D003866), anxiety (MESH:D001007), pain (MESH:D010146)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12258309/full.md

---
Source: https://tomesphere.com/paper/PMC12258309